Immunity and Immune Suppression in Human Ovarian Cancer

Preston, Claudia C.; Goode, Ellen L.; Hartmann, Lynn C.; Kalli, Kimberly R.; Knutson, Keith L.

doi:10.2217/imt.11.20

Cited by 112 publications

(95 citation statements)

References 153 publications

(164 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data point to a mechanism of immune suppression in ovarian cancer either by overexpression of Tregs or by the tumor itself by escaping the immune response by molecular mimicry or by escaping immunosurveillance 42,43 . Additional eveidence has reinforced the involvement of Tregs in ovarian cancer.…”

Section: Proteins Involved In Immune Response Modulationmentioning

confidence: 85%

MALDI-MSI and Ovarian Cancer Biomarkers

Longuespée

Boyon²,

Kerdraon³

et al. 2012

Advances in Cancer Management

View full text Add to dashboard Cite

Section: Proteins Involved In Immune Response Modulationmentioning

confidence: 85%

MALDI-MSI and Ovarian Cancer Biomarkers

Longuespée

Boyon²,

Kerdraon³

et al. 2012

Advances in Cancer Management

View full text Add to dashboard Cite

“…naturally occurring Tregs with CD4 þ CD25 þ FOXP3 þ phenotype and induced Tregs with variable CD25 expression (17). Tregs depend on PD-1, PD-L1 (programmed cell death ligand 1), or CTL-associated antigen 4 (CTLA-4) to carry out antitumor immune responses (18,19).…”

Section: Introductionmentioning

confidence: 99%

Cytotoxicity of Human Endogenous Retrovirus K–Specific T Cells toward Autologous Ovarian Cancer Cells

Rycaj

Plummer

Yin

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To determine whether HERV-K envelope (ENV) protein could function as a tumor-associated antigen and elicit specific T-cell responses against autologous ovarian cancer cells.Experimental Design: The expression of HERV-K transcripts and ENV protein, the presence of serum antibodies against HERV-K, reverse transcriptase (RT) activities, and cellular immune responses in primary ovarian cancer tissues and patient blood samples were analyzed and compared with samples from patients with benign ovarian diseases and normal female donors.Results: Ovarian cancer cells in primary tumors and ascites expressed markers of cancer stem cells and markers of both mesenchymal and epithelial cells. Expression of HERV transcripts and HERV-K ENV protein and reverse transcriptase activities were higher in ovarian cancer compared with adjacent normal and benign tissues. The ovarian cancer patient plasma also had high reverse transcriptase activities and the ovarian cancer patient sera contained HERV-K immunoreactive antibodies. HERV-K-specific T cells generated from autologous dendritic cells pulsed with HERV-K ENV antigens exhibited phenotypes and functions consistent with a cellular immune response including T-cell proliferation, IFNg production, and HERV-K-specific cytotoxic T lymphocyte (CTL) activity. Significantly higher CTL lysis of autologous tumor cells than of uninvolved normal cells was demonstrated in patients with ovarian cancer than patients with benign diseases and further enhanced lysis was observed if T regulatory cells were depleted.Conclusion: Endogenous retroviral gene products in ovarian cancer may represent a potentially valuable new pool of tumorassociated antigens for targeting of therapeutic vaccines to ovarian cancer.

show abstract

“…Evidence from several studies indicates that T lymphocytes capable of recognizing EOC cells are present at the tumor site (2,3) and that T-cell-mediated immunity may have an impact on clinical course of EOC (3). However, similar to other tumors, EOC has the ability to escape from immune system control through several mechanisms (4,5).…”

Section: Introductionmentioning

confidence: 99%

The IL-18 Antagonist IL-18–Binding Protein Is Produced in the Human Ovarian Cancer Microenvironment

Carbotti

Barisione

Orengo

et al. 2013

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Interleukin (IL)-18 is an immune-enhancing cytokine, which induces IFN-g production, T-helper 1 responses, and antitumor effects. In turn, IFN-g stimulates IL-18-binding protein production, which blocks IL-18 activity. In view of the potential use of IL-18 in epithelial ovarian cancer (EOC) immunotherapy, here, we studied IL-18BP expression and its regulation by cytokines in EOC cells in vitro and in vivo.Experimental Design: Expression and production of IL-18BP in EOC cell lines, primary ovarian carcinomas, and the corresponding normal tissues, patients' serum, and ascites were investigated by immunochemistry, ELISA, screening of gene expression profiles, and reverse-transcription PCR.Results: Analysis of gene expression profiles revealed that IL18BP mRNA is increased in EOC tumors compared with normal ovary cells. Release of IL-18BP was detectable in EOC sera and to a greater extent in the ascites, indicating production at the tumor site. Indeed, immunochemical analyses on cells isolated from the ascites and on tumor sections indicated that IL-18BP is expressed in both tumor cells and tumor-associated leukocytes, which displayed a CD3 À CD20EOC cell lines do not constitutively express IL-18BP. However, its release is inducible both by IFN-g stimulation in vitro and by xenotransplantation of EOC cells in immune-deficient mice, suggesting a role for the microenvironment. In vitro experiments and immunochemistry indicated that IL-27 is also involved in IL-18BP upregulation in EOC cell lines and primary cells through STAT1 activation. Together, these data indicate that IL-18BP, which is produced in EOC in response to microenvironmental factors, may inhibit endogenous or exogenous IL-18 activity.

show abstract

Immunity and Immune Suppression in Human Ovarian Cancer

Cited by 112 publications

References 153 publications

MALDI-MSI and Ovarian Cancer Biomarkers

MALDI-MSI and Ovarian Cancer Biomarkers

Cytotoxicity of Human Endogenous Retrovirus K–Specific T Cells toward Autologous Ovarian Cancer Cells

The IL-18 Antagonist IL-18–Binding Protein Is Produced in the Human Ovarian Cancer Microenvironment

Contact Info

Product

Resources

About